Category - Markets

H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday. Originally spun-off from Sandoz, Austria-based Nabriva has in...

Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday. Protagonist is aiming to become the...

Leerink Partners initiated coverage of Endologix (NASDAQ:ELGX) with a “market perform” rating and $13 price target. The stock closed at $12.22 on Friday. Endologix is the largest abdominal aortic aneurysm (AAA) pure...

Atossa Genetics (NASDAQ:ATOS) has priced a public offering of 1,150,000 common shares at a price of $2.50 a share for gross proceeds of about $2,875,000. Atossa Genetics also granted underwriters a 45-day option to...

OPKO Health (NASDAQ:OPK) has completed the acquisition of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) by way of a plan of arrangement. Under the transaction, shareholders of Transition will receive about 6.4 million...

Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday. Analyst Joseph Pantginis writes that Neuralstem has undergone a...

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the...

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively. Tactile makes pneumatic...

Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday. “Now with two solid quarters in a row of stable-to...

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier. “Curing chronic hepatitis B infections is the next frontier...